<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03876821</url>
  </required_header>
  <id_info>
    <org_study_id>C18-31</org_study_id>
    <nct_id>NCT03876821</nct_id>
  </id_info>
  <brief_title>Collect of Cord Blood From Subjects at Risk for Sickle Cell Disease, for the Purpose of Laboratory Research</brief_title>
  <acronym>DREPACORD</acronym>
  <official_title>Collect of Cord Blood From Subjects at Risk for Sickle Cell Disease, for the Purpose of Laboratory Research</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Sud Francilien</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study consists in collecting umbilical cord blood cells from newborns at risk of sickle
      cell disease, to perform laboratory experiments aiming to characterize the cells with HbS/HbS
      mutation, to develop methods to prepare, to gene-modify and to preserve these cells.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnant individuals carrying at least one HbS allele will be included in the study to
      collect the umbilical cord blood of the child at birth. Collected cells will be used
      anonymously for genetic and bioexperimental laboratory research, aiming to develop autologous
      gene therapy for sickle cell disease.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of samples with HbS/HbS genotype</measure>
    <time_frame>3 years</time_frame>
    <description>Measured by DNA sequencing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of samples with bio-experimental data</measure>
    <time_frame>4 years</time_frame>
    <description>Consisting of cellular characterization, transduction and cell processing data</description>
  </secondary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Sickle Cell Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA from cord blood cells.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study includes pregnant women, aged 18-45 years of age, carrying at least one HbS
        allele, and who are followed and giving birth at the maternity unit of the Centre
        Hospitalier Sud Francilien in Evry, France.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women, giving birth at CHSF and consenting to the collect and study of
             placental blood after delivery

          -  Age 18 to 45 years

          -  Biological testing of the participant includes hemoglobin electrophoresis and shows at
             least one HbS allele

        Exclusion Criteria:

          -  Lack of written consent

          -  Minors (not 18 years old) or under guardianship

          -  Diseases : HIV, Hepatitis B, Hepatitis C or HTLV (Human T Leukemia Virus).
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Giving birth</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc Rigonnot, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHSF</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Galy, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ismahane GUIMIOT</last_name>
    <phone>+33 (0)1 82 53 35 36</phone>
    <email>ismahane.guimiot@inserm.fr</email>
  </overall_contact>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>February 27, 2019</study_first_submitted>
  <study_first_submitted_qc>March 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>March 13, 2019</last_update_submitted>
  <last_update_submitted_qc>March 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

